Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib and Nivolumab Simultaneous Combination Therapy for Advanced and Metastatic Solid Tumors: Phase I Clinical Trial

NCT03406871 is registered in ClinicalTrials.gov with Kohei Shitara as lead sponsor.

NCT NCT03406871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03406871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib and Nivolumab Simultaneous Combination Therapy for Advanced and Metastatic Solid Tumors: Phase I Clinical Trial
Lead sponsor
Kohei Shitara
Phase
Phase 1
Overall status
Completed
Start date
January 15, 2018
Completion date
December 15, 2020
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and metastatic solid tumor